GlassScriptPhysician profile
Christa Caudill
NPI 1376992537
$2,950.48
in general payments reported to CMS, 2019-2025
28 companies · $949 in 2025
The $949 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.76 · 2022: $441 · 2023: $775 · 2024: $774 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.36 | 2022-2025 | |
| Lilly USA, LLC | $336.69 | 2023-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $334.07 | 2023-2025 | |
| Corcept Therapeutics | $229.57 | 2024-2025 | Korlym |
| Novo Nordisk INC | $209.48 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $127.92 | 2022-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.41 | 2023-2025 | Caplyta |
| Indivior INC. | $97.48 | 2024-2025 | Sublocade |
| Glaxosmithkline, LLC. | $86.10 | 2022-2025 | Bexsero, Shingrix, Arexvy |
| Alkermes, INC. | $84.95 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $71.73 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $52.64 | 2023-2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $51.29 | 2024-2025 | Rexulti |
| Lundbeck LLC | $48.21 | 2025 | Rexulti |
| Exact Sciences Corporation | $48.01 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.83 | 2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Insulet Corporation | $22.23 | 2023 | Omnipod |
| Supernus Pharmaceuticals, INC. | $21.12 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $21.12 | 2025 | Zurzuvae |
| Xeris Pharmaceuticals, INC. | $19.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.11 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.38 | 2025 | Airsupra |
| Gilead Sciences, INC. | $16.05 | 2023 | |
| Astellas Pharma US INC | $15.54 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $14.43 | 2022 | |
| Medtronic, INC. | $14.42 | 2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.90 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Caudill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.